Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details)

v3.24.1.u1
Commitments and Contingencies (Details) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended
Jun. 15, 2012
Mar. 31, 2024
Commitments and Contingencies [Abstract]    
Milestone payment $ 1  
Description of royalty payment   Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.
Royalty payments percentage 2.00%